edotreotide has been researched along with Carcinoma, Small Cell in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buitrago, C; Herrmann, R; Maecke, H; Mueller-Brand, J; Pless, M; Waldherr, C | 1 |
| Bakker, W; Chen, T; Jamar, F; Krenning, E; Kvols, L; Liu, J; Pauwels, S; Schran, H; Smith, MC; Valkema, R; Yeh, CM | 1 |
1 review(s) available for edotreotide and Carcinoma, Small Cell
| Article | Year |
|---|---|
OctreoTher: ongoing early clinical development of a somatostatin-receptor-targeted radionuclide antineoplastic therapy.
Topics: Animals; Breast Neoplasms; Carcinoma, Small Cell; Dose-Response Relationship, Radiation; Female; Humans; Indium Radioisotopes; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasms; Neuroendocrine Tumors; Octreotide; Radiopharmaceuticals; Receptors, Somatostatin; Somatostatin; Yttrium Radioisotopes | 2000 |
1 trial(s) available for edotreotide and Carcinoma, Small Cell
| Article | Year |
|---|---|
Targeted radiotherapy for small cell lung cancer using 90Yttrium-DOTATOC, an Yttrium-labelled somatostatin analogue: a pilot trial.
Topics: Aged; Carcinoma, Small Cell; Disease Progression; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Octreotide; Radionuclide Imaging; Radiopharmaceuticals; Yttrium Radioisotopes | 2004 |